Jason O'Byrne, MBA, currently holds the position of Executive Vice President and Chief Financial Officer at Vir Biotechnology Inc., a company focused on developing treatments for infectious diseases. With an extensive background in finance and strategic management, O'Byrne has been instrumental in guiding Vir Biotechnology through its growth and development phases. He joined the company in 2017 and has since played a pivotal role in shaping its financial strategy, which has been crucial for its advancement in the biopharmaceutical industry. Prior to his tenure at Vir Biotechnology, O'Byrne held significant roles that honed his expertise in financial management and corporate strategy. He served as the Chief Financial Officer at Receptos Inc., where he was instrumental in leading the company through its successful acquisition by Celgene Corporation for $7.2 billion. Before Receptos, O'Byrne worked at Amgen Inc. in various capacities, including Vice President of Finance, where he managed global financial planning and analysis. His strategic vision and financial acumen have been recognized through his contributions to the growth and success of the companies he has served. In his current role at Vir Biotechnology, O'Byrne oversees all aspects of the company's financial operations, including financial planning, accounting, and investor relations. His leadership has been vital in securing funding and managing resources to support the company's research and development efforts. Under his guidance, Vir Biotechnology has made significant strides in advancing its pipeline of innovative therapies, positioning the company as a leader in the fight against infectious diseases. O'Byrne's commitment to excellence and his strategic foresight continue to drive the company forward, ensuring its continued success and impact in the biopharmaceutical sector.